Stipple Bio has emerged from stealth with plans to initiate multiple early-stage clinical studies for its lead precision oncology candidate, supported by a $100 million series A financing round. The funding, described by the company as heavily oversubscribed, is expected to provide financial runway through 2029.
The round was co-led by RA Capital, a16z Bio+Health, and Nextech Invest, according to an April 6 announcement. Additional participation came from existing investors including Emerson Collective Investments, managed by Yosemite, Google Ventures, LoLa Capital Partners, and GordonMD Global Investments, among others.
The company intends to use the proceeds to advance its lead asset, STP-100, into clinical development early next year. STP-100 is an antibody-drug conjugate (ADC) designed with tumor-specific binding properties aimed at minimizing toxicity associated with interactions in both cancerous and healthy tissues. According to Stipple, the therapy leverages binders that selectively target tumor cells.
The development of STP-100 is based on the company’s proprietary Pointillist platform. The system is described as modality-agnostic and is designed to identify tumor-specific cell surface epitopes, which are the regions of antigens recognized by antibodies or T-cell receptors. These identified epitopes are then used to guide the development of potential cancer therapies.
The company’s name reflects the concept of stippling, a technique involving the use of small dots, which parallels the identification of specific binding points on cell surfaces. Through its platform, Stipple aims to distinguish between epitopes present on tumor cells and those found on normal tissue.
Chief Executive Officer Jeff Landau explained that this differentiation enables the company to improve the therapeutic index of its drug candidates. By focusing on differences between tumor and healthy cell epitopes, the company seeks to identify selective binding opportunities.
“We are looking for specific binding epitopes and have a map of different options, but we are looking for the ones that have binding opportunities for cancer cells that don’t bind to normal cells,” Landau said. “If you know how to do it the right way, there are a lot of them.”
While the specific indication for STP-100 has not been disclosed, the company stated that the therapy targets a clinically validated pathway that has historically been constrained by challenges in achieving effective tumor-specific binding. Landau indicated that the approach is intended to make such targets more compatible with potent therapeutic modalities.
Beyond its lead program, Stipple has identified additional tumor-specific binding opportunities. The company noted that it has received interest from other biopharmaceutical firms regarding potential collaborations involving its platform. However, Landau emphasized that the current focus remains on advancing wholly owned programs, particularly STP-100, with partnership discussions considered only if suitable opportunities arise.
A portion of the financing will also be allocated toward expanding the company’s pipeline by identifying further tumor-specific cell surface epitopes. This effort is intended to support the development of additional oncology candidates.
Stipple Bio was founded in 2022 by researchers from the University of California, San Francisco. The company’s approach centers on targeting tumor-specific epitopes and discovering previously untreatable targets, with the aim of developing safer and more effective therapies.
About STP-100 and Clinical Progress
At the center of the Stipple Bio strategy is STP-100, a next-generation antibody-drug conjugate (ADC).
Key highlights of Stipple Bio’s lead asset:
- Designed to target tumor-specific epitopes
- Aims to reduce “on-target, off-tumor” toxicity
- Expected to enter early-stage clinical trials in 2027
The advancement of STP-100 positions Stipple Bio as a rising player in precision oncology therapeutics.
Pointillist Platform Advantage
A core differentiator for Stipple Bio is its proprietary Pointillist platform.
This platform enables Stipple Bio to:
- Identify tumor-specific cell surface epitopes
- Develop highly targeted therapies
- Unlock previously undruggable cancer targets
By focusing on epitope-level precision, Stipple Bio aims to significantly improve therapeutic index and patient outcomes.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
